Sunday, January 26, 2014
Red yeast rice
Other common names: Hong qu
Latin name: Monascus purpureus Went. [Monascaceae]
Red yeast rice is a traditional Chinese fermented product made
from a red yeast, Monascus purpureus Went., that is grown on rice.
Documentation of the use of red yeast rice extends back to the Tang
dynasty in 800 A.D. Red yeast rice products contain a group of compounds
called the monacolins, which are a family of polyketides. The
monacolins have been identified as inhibitors of an enzyme involved
in the endogenous biosynthesis of cholesterol, 3-hydroxy-3-methylglutaryl
coenzymeA (HMG-CoA) reductase. One of the monacolins,
monacolin K, is identical to lovastatin. Lovastatin is a common cholesterol-
lowering statin drug that is manufactured by Merck and Co.,
Inc., West Point, Pennsylvania (Heber et al., 1999; Schulz, Hänsel,
and Tyler, 2001).
Cholestin™ capsules are manufactured by Pharmanex, a subsidiary
of Nu Skin Enterprises, Provo, Utah. The capsules contained 600
mg red yeast rice product, including 0.4 percent monacolins by
weight (RY-2), approximately half of which (0.2 percent) were monacolin
K. Recent court action by Merck, due to the similarity of
monacolin K in Cholestin to lovastatin (mevinolin) in Mevacor®,
blocked the sale of Cholestin as originally formulated in the United
States. The original Cholestin, containing red yeast rice, is still available
in other countries. The new U.S. formulation includes, as a substitute,
a beeswax extract called policosanol. According to Pharmanex,
policosanol is a safe and effective ingredient that successfully
maintains existing normal cholesterol levels, although the new formulation
has not been tested clinically. Each capsule of Cholestin
sold in the United States now contains 15 mg policosanol (beeswax
extract 5:1).
Monascus purpureus Went. yeast is called Xue-zhi-kang in Chinese.
The Xue-zhi-kang product (RY-1) produced by Wei-Xin Company
(China) delivered a daily dose of 1.2 g red yeast rice containing
13.5 mg total monacolins.
The red yeast rice product called Zhitai, produced by WBL Peking
University Biotech Co. Ltd. (China) delivered 10-13 mg total monacolins
in a 5 g daily dose. According to a spokesperson from Pharmanex,
the former two products were prototypes studied in the development of
the original Cholestin.
Hyperlipidemia (Elevated Blood Lipid Levels)
A double-blind, placebo-controlled, randomized trial included 83
subjects with slightly elevated cholesterol (total serum cholesterol
204 to 338 mg/dl, LDL cholesterol 128 to 277 mg/dl, triacylglycerol
55 to 246 mg/dl, and HDL cholesterol 30 to 95 mg/dl). Participants
received either 2.4 g red yeast rice (Cholestin) or placebo for 12
weeks and were put on the American Heart Association’s Step I diet.
After eight and twelve weeks, total serum cholesterol and LDL cholesterol
measurements in the treatment group decreased significantly
from baseline and in comparison to placebo. The reduction in total
cholesterol in the treatment group after 12 weeks compared with
baseline was roughly 40 mg/dl. Triacylglycerol levels also decreased
at week 8 in comparison to placebo, and at weeks 8 and 12 in comparison
to baseline. HDL cholesterol levels did not alter significantly in
either group (Heber et al., 1999).
Pygeum
Other common names: African plum
Latin name: Prunus africana (Hook. f.) Kalkman [Rosaceae]
Latin synonyms: Pygeum africanum Hook. f.
Plant part: Bark
Pygeum bark has been traditionally used in central and southern
Africa to assist bladder and urinary function. In this traditional use,
the bark is ground into powder and mixed with milk. Modern formulation
of this botanical is a lipophilic extract of the bark. At least three
types of active compounds may be responsible for the therapeutic action
of the extract: pentacyclic terpenes, phytosterols, and ferulic acid
esters (Schulz, Hänsel, and Tyler, 2001).
Tadenan® is manufactured in France by Laboratoires Fournier.
The capsules contain 50 mg of a lipophilic extract of pygeum bark.
Tadenan is not sold in the United States.
Pigenil contains a pygeum bark extract (PrunuSelect™) manufactured
by Indena S.p.A., Italy. This extract has a plant to extract ratio
of 180:1, and is standardized to contain 11.7 to 14.3 percent sterols as
beta-sitosterol. Pigenil, in 50 mg capsules, was originally manufactured
by Inverni della Beffa in Italy. This product is not available in
the United States.
Prostatonin® contains extracts of both pygeum bark and nettle
(Urtica dioica L. spp. dioica) roots. This product is manufactured by
Pharmaton S.A. in Switzerland, and is sold in the United States by
Pharmaton Natural Health Products. It is available in softgel capsules
containing 25 mg pygeum extract, PY102 (200:1), and 300 mg nettle
extract, UR102 (5:1).
Pygeum preparations have been assessed in clinical studies for the
treatment of symptomatic benign prostatic hyperplasia (BPH), also
known as benign prostatic hypertrophy and prostatic adenoma. BPH
is a nonmalignant enlargement of the prostate common in men over
40 years of age. The symptoms of BPH include increased urinary urgency
and frequency, urinary hesitancy, intermittency, sensation of
incomplete voiding, and decreased force of the stream of urine. BPH
is linked with a normal change in hormone levels that occurs with aging.
Testosterone levels decrease while estrogen levels remain constant.
This change is implicated in BPH, since estrogens induce hyperplasia
(cell growth) in laboratory experiments. Further, BPH is
associated with an increase in the activity of 5-alpha-reductase, the
enzyme that converts testosterone to dihydrotesterone (DHT). The
levels of DHT are not increased, but the number of androgen receptors
seems to be. DHT has a greater affinity for androgen receptors
than testosterone, and is thought to modulate prostatic growth. However,
the pathology of BPH is not completely understood, and although
BPH is associated with prostate enlargement, the size of the
gland is not necessarily indicative of the degree of obstruction of the
urethra and the extent of symptoms (Barrett, 1999).
Predominant pharmaceutical treatments for BPH include alphareceptor
blockers and 5-alpha-reductase inhibitors. Alpha-receptor
blockers (e.g., prozosin, terazosin) are thought to relax smooth muscle
in the bladder neck and within the prostate, and thus reduce symptoms.
Five-alpha reductase inhibitors (e.g., finasteride) prevent the
transformation of testosterone into DHT. The rationale for this treatment
is that prostate enlargement may be linked to activation of androgen
receptors by DHT and a reduction in testosterone levels
(Barrett, 1999).
The clinical mode of action of pygeum has not been established,
but biochemical studies indicate that it has anti-inflammatory activity
and may inhibit 5-alpha-reductase. Nettle root extract, which is combined
with pygeum extract in the product Prostatonin®, may have
similar activity. Preparations of grass pollen and saw palmetto have
also been assessed clinically for treatment of BPH, and more information
about these botanicals is given in their sections in this book.
The mechanism of action of these botanicals is also not established,
but grass pollen has demonstrated anti-inflammatory activity, and
may reduce the growth of epithelial cells and fibroblasts. Suggested
pharmacological actions for saw palmetto include antiandrogenic,
anti-inflammatory, antiproliferative, and smooth muscle relaxation
(Marandola, et al., 1997; Awang, 1997; Barrett, 1999).
Subscribe to:
Posts (Atom)


